5 results match your criteria: "Alzheimer's Disease and Memory Disorders Center at Rhode Island Hospital[Affiliation]"
Evaluating Lecanemab Eligibility for Patients in Skilled Nursing Facilities With Alzheimer Disease or Mild Cognitive Impairment.
J Am Med Dir Assoc
November 2024
Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, USA; Alzheimer's Disease and Memory Disorders Center at Rhode Island Hospital, Providence, RI, USA; Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.
Diabetes Obes Metab
August 2024
Hinda and Arthur Marcus Institute for Aging Research and Department of Medicine, Hebrew SeniorLife, Boston, Massachusetts, USA.
Aim: Studies examining the safety and effectiveness of sodium-glucose cotransporter-2 inhibitors (SGLT2is) versus glucagon-like peptide-1 receptor agonists (GLP-1RAs) among community-dwelling adults may not generalize to nursing home (NH) residents, who are typically older and more multimorbid. We compared the safety and cardiovascular effectiveness of SGLT2is and GLP-1RAs among US NH residents.
Materials And Methods: Eligible individuals were aged ≥66 years with type 2 diabetes mellitus and initiated an SGLT2i or GLP-1RA in an NH between 2013 and 2018.
Benefits and Harms of Standard Versus Reduced-Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation.
J Am Heart Assoc
November 2023
Department of Health Services, Policy, and Practice Brown University School of Public Health Providence RI.
Article Synopsis
- A study analyzed the use of direct oral anticoagulants (DOACs) in older adults (≥65 years) with nonvalvular atrial fibrillation living in nursing homes, finding that 48% received reduced doses.
- The study showed that standard dosing was linked to a higher rate of major bleeding compared to reduced doses, particularly in those over 80 years old and with lower body mass indexes.
- However, there was no significant difference in all-cause mortality or thrombotic events between standard and reduced dosing, suggesting that reduced-dose DOACs may be safer for many older adults with multiple health issues.
Novel blood test for early biomarkers of preeclampsia and Alzheimer's disease.
Sci Rep
August 2021
Department of Pediatrics, Women and Infants Hospital-Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI, 02905, USA.
A non-invasive and sensitive blood test has long been a goal for early stage disease diagnosis and treatment for Alzheimer's disease (AD) and other proteinopathy diseases. We previously reported that preeclampsia (PE), a severe pregnancy complication, is another proteinopathy disorder with impaired autophagy. We hypothesized that induced autophagy deficiency would promote accumulation of pathologic protein aggregates.
View Article and Find Full Text PDFAnticholinergic/Sedative Drug Burden and Subjective Cognitive Decline in Older Adults at Risk of Alzheimer's Disease.
J Gerontol A Biol Sci Med Sci
May 2021
Alzheimer's Disease and Memory Disorders Center at Rhode Island Hospital, Providence.
Article Synopsis
- Anticholinergic/sedative drug use, assessed through the Drug Burden Index (DBI), is linked to cognitive decline in older adults, particularly those at risk of Alzheimer's disease.
- A study involving 206 older adults found that those with higher DBI values reported more severe subjective cognitive decline (SCD), especially among participants aged 65 and up.
- The findings suggest that increased drug exposure may serve as a pre-clinical indicator of neurodegenerative conditions, highlighting the need for further research to explore this potential connection.